Japan's Transgenic And National Medical Center Collaborate On New Flu Diagnosis
This article was originally published in PharmAsia News
Tokyo-based International Medical Center of Japan and biotech firm Transgenic will jointly research and develop new antibodies for flu virus diagnosis. The center will use gene-engineered mice provided by Transgenic to develop an H1N1 antibody. The antibody will help to quickly diagnose the flu in patients. The two aim to commercialize the technology inside medical facilities this winter. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.